Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Computational Comparative Pharmacology: Designing Better Drugs for Animals (and Humans)

Modeling and simulation can help veterinarians provide better care for animals and guide research study design thereby maximizing the knowledge gained from research studies whilst minimizing the number of animals used. In this webinar, we looked at how PBPK modeling can be used to predict the absorption, distribution, metabolism, and excretion of drugs in humans and other animal species.

Speaker(s): Ronette Gehring
Solution: Model-informed Drug Development, PBPK Modeling & Simulation, PK/PD Modeling & Simulation
More Info

Making Sense of 6MWT Variability: Developing a Disease Progression Model for DMD

Duchenne Muscular Dystrophy (DMD) is a life-threatening, sex-linked, pediatric rare disease, primarily affecting boys. It is characterized by progressive muscle degeneration, weakness, and eventually functional loss. DMD is caused by a mutation in the dystrophin gene, a protein needed to maintain muscle integrity, and for improving signaling and growth in differentiation of the muscle tissue. […]

Author(s): Lora Hamuro
Solution: PK/PD Modeling & Simulation
Therapeutic Area: Pediatrics, Rare/Orphan Disease
More Info

Using a Pharmacology to Payer Framework to Support Product Development

Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains with a variety of domain-specific approaches and applications. The pharmacology to payer (P2P) concept is a way to connect independent domains to address drug development market failures. As an initial proof of concept, we collaborated with a team of clinical pharmacologists, […]

Author(s): Carl Kirkpatrick, Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info

Using Virtual Twin Technology to Predict Drug Exposure in Individual Patients

In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.

Speaker(s): Tom Polasek
Solution: PBPK Modeling & Simulation
Therapeutic Area: Central Nervous System
More Info

How to Plan and Implement a Pharmacology to Payer Framework

Pharmacology to the payer (P2P) is an innovative approach to create a framework for dialogue between drug sponsors, regulators, and payers. The core structure is the sequential linking of quantitative mathematical models—pharmacology, pharmacokinetics/pharmacodynamics (PK/PD), disease progression, epidemiology, health utilization, and health economics. In this blog post, we discuss how working with an amazing team of […]

Author(s): Carl Kirkpatrick and Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info

Pharmacology to Payer: One Quantitative Drug Development Framework to Rule Them All

In JRR Tolkien’s Lord of the Rings, the power of the one ring forged by the evil sorcerer, Sauron, is used to control all of the disaggregated, independent kingdoms of Middle Earth. Similarly, but without the malice, the “pharmacology to the payer” (P2P) quantitative framework can be viewed as a way to unite and connect […]

Author(s): Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info